Claims
- 1. A compound of the formula (I) below, or a pharmacologically acceptable salt, ester or other derivative thereof:
- 2. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R1 is an unsubstituted aryl group, or an aryl group which is substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group 1.
- 3. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R1 is an unsubstituted phenyl or naphthyl group, or a phenyl or naphthyl group in which said group is substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β.
- 4. The compounds according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R1 is an unsubstituted phenyl group, or a phenyl group which is substituted with one or more substituents selected from the group consisting of Substituent group α1 and Substituent group β1,
- 5. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R1 is an unsubstituted phenyl group, or a phenyl group which is substituted with one or more substituents selected from the group consisting of a halogen atom, a halogeno lower alkyl group and a halogeno lower alkoxy group.
- 6. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R1 is a phenyl, 4-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 3,4-difluorophenyl, 3,4,5-trifluorophenyl, 3-chloro-4-fluorophenyl, 3-difluoromethoxyphenyl or 3-trifluoromethylphenyl group.
- 7. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R2 is a 5- or 6-membered heteroaryl group which has one or two nitrogen atoms, or a 5- or 6-membered heteroaryl group which has one or two nitrogen atoms in which said group is substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β.
- 8. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R2 is an unsubstituted pyridyl or pyrimidinyl group, or a pyridyl or pyrimidinyl group in which said group is substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β.
- 9. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R2 is an unsubstituted 4-pyridyl or 4-pyrimidinyl group, or a 4-pyridyl or 4-pyrimidinyl group in which said group is substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β.
- 10. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R2 is an unsubstituted 4-pyridyl or 4-pyrimidinyl group, or a 4-pyridyl or 4-pyrimidinyl group in which said group is substituted at the 2-position thereof with one substituent selected from the group consisting of Substituent group α and Substituent group β.
- 11. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R2 is an unsubstituted 4-pyridyl or 4-pyrimidinyl group, or a 4-pyridyl or 4-pyrimidinyl group which is substituted at the 2-position thereof with one substituent selected from the group consisting of methoxy, amino, methylamino, benzylamino and α-methylbenzylamino.
- 12. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R3 is a group of formula (IIa) or formula (IIb), and B is a 5- or 6-membered heterocyclic ring which has one ring nitrogen atom and optionally has one further ring heteroatom or ring group selected from the group consisting of a nitrogen atom, an oxygen atom, a sulfur atom, an >SO group and an >SO2 group, said ring may be saturated or unsaturated and may be fused with a group selected from aryl groups, heteroaryl groups, cycloalkyl groups and heterocyclyl groups.
- 13. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R3 is a group of formula (IIa) or formula (IIb), and B is a 5- or 6-membered heterocyclic ring which comprises the group D, the group E and three or four carbon atoms, said ring may be saturated or unsaturated and may be fused with a group selected from aryl groups, heteroaryl groups, cycloalkyl groups and heterocyclyl groups.
- 14. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R3 is a group of formula (IIa).
- 15. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein B is a pyrrolidine ring or a pyrroline ring.
- 16. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein m is 1.
- 17. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R5 is one or two substituents which are independently selected from the group consisting of hydrogen atoms, Substituent group α, Substituent group β and Substituent group γ1, wherein
- 18. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R5 is one or two substituents which are independently selected from the group consisting of hydrogen atoms, hydroxy groups, halogen atoms, lower alkoxy groups, lower alkylthio groups, halogeno lower alkoxy groups, lower alkyl groups, halogeno lower alkyl groups, oxo groups, unsubstituted aryl groups, aryl groups which are substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β; lower alkylene groups; lower alkylenedioxy groups and lower alkylsulfonyl groups.
- 19. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R5 is one or two substituents which are independently selected from the group consisting of hydrogen atoms, hydroxy groups, fluorine atoms, chlorine atoms, methoxy groups, ethoxy groups, propoxy groups, methyl groups, ethyl groups, propyl groups, unsubstituted phenyl groups and phenyl groups which are substituted with substituents selected from the group consisting of Substituent group α and Substituent group β.
- 20. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R5 is one substituent which is independently selected from the group consisting of hydrogen atoms, methoxy groups, methyl groups, ethyl groups, propyl groups and phenyl groups.
- 21. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R4 is a hydrogen atom, an unsubstituted lower alkyl group, a lower alkyl group which is substituted with one or more substituents from Substituent group α, an aryl group substituted with one or more substituents selected from the group consisting of Substituent group α, Substituent group β and Substituent group γ; an unsubstituted heterocyclyl group, or a heterocyclyl group substituted with one or more substituents selected from the group consisting of Substituent group α, Substituent group β, and Substituent group γ.
- 22. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R4 is a hydrogen atom, a lower alkyl group, a halogeno lower alkyl group, or a phenyl group substituted with one or more substituents selected from the group consisting of Substituent group α, Substituent group β and Substituent group γ.
- 23. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein A is a pyrazole ring having one substituent R4 or an imidazole ring having one substituent R4.
- 24. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein A is a pyrazole ring having one substituent R4.
- 25. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R1 is an unsubstituted aryl group, or an aryl group which is substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β;
R2 is a 5- or 6-membered heteroaryl group which has one or two nitrogen atoms, or a 5- or 6-membered heteroaryl group which has one or two nitrogen atoms in which said group is substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β; R3 is a group of formula (IIa) or formula (IIb), and B is a 5- or 6-membered heterocyclic ring which has one ring nitrogen atom and optionally has one further ring heteroatom or ring group selected from the group consisting of a nitrogen atom, an oxygen atom, a sulfur atom, an >SO group and an >SO2 group, said ring may be saturated or unsaturated and may be fused with a group selected from aryl groups, heteroaryl groups, cycloalkyl groups and heterocyclyl groups; and R5 is one or two substituents which are independently selected from the group consisting of hydrogen atoms, Substituent group α, Substituent group β and Substituent group γ1, wherein Substituent group γ1 is selected from the group consisting of oxo groups, hydroxyimino groups, lower alkoxyimino groups, lower alkylene groups, lower alkylenedioxy groups, lower alkylsulfinyl groups, lower alkylsulfonyl groups, unsubstituted aryl groups, and aryl groups which are substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β.
- 26. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R1 is an unsubstituted phenyl or naphthyl group, or a phenyl or naphthyl group in which said group is substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β;
R2 is an unsubstituted pyridyl or pyrimidinyl group, or a pyridyl or pyrimidinyl group in which said group is substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β; R3 is a group of formula (IIa) or formula (IIb), and B is a 5- or 6-membered heterocyclic ring which has one ring nitrogen atom and optionally has one further ring heteroatom or ring group selected from the group consisting of a nitrogen atom, an oxygen atom, a sulfur atom, an >SO group and an >SO2 group, said ring may be saturated or unsaturated and may be fused with a group selected from aryl groups, heteroaryl groups, cycloalkyl groups and heterocyclyl groups; and R5 is one or two substituents which are independently selected from the group consisting of hydrogen atoms, hydroxy groups, halogen atoms, lower alkoxy groups, lower alkylthio groups, halogeno lower alkoxy groups, lower alkyl groups, halogeno lower alkyl groups, oxo groups, unsubstituted aryl groups, aryl groups which are substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β; lower alkylene groups; lower alkylenedioxy groups and lower alkylsulfonyl groups.
- 27. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R1 is an unsubstituted phenyl or naphthyl group, or a phenyl or naphthyl group in which said group is substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β;
R2 is an unsubstituted pyridyl or pyrimidinyl group, or a pyridyl or pyrimidinyl group in which said group is substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β; R3 is a group of formula (IIa) or formula (IIb), and B is a 5- or 6-membered heterocyclic ring which comprises the group D, the group E and three or four carbon atoms, said ring may be saturated or unsaturated and may be fused with a group selected from aryl groups, heteroaryl groups, cycloalkyl groups and heterocyclyl groups; and R5 is one or two substituents which are independently selected from the group consisting of hydrogen atoms, hydroxy groups, halogen atoms, lower alkoxy groups, lower alkylthio groups, halogeno lower alkoxy groups, lower alkyl groups, halogeno lower alkyl groups, oxo groups, unsubstituted aryl groups, aryl groups which are substituted with one or more substituents selected from the group consisting of Substituent group α and Substituent group β; lower alkylene groups; lower alkylenedioxy groups and lower alkylsulfonyl groups.
- 28. The compounds according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R1 is an unsubstituted phenyl group, or a phenyl group which is substituted with one or more substituents selected from the group consisting of Substituent group al and Substituent group
- 29. The compounds according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R1 is an unsubstituted phenyl group, or a phenyl group which is substituted with one or more substituents selected from the group consisting of Substituent group α1 and Substituent group
- 30. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R1 is an unsubstituted phenyl group, or a phenyl group which is substituted with one or more substituents selected from the group consisting of a halogen atom, a halogeno lower alkyl group and a halogeno lower alkoxy group;
R2 is an unsubstituted 4-pyridyl or 4-pyrimidinyl group, or a 4-pyridyl or 4-pyrimidinyl group in which said group is substituted at the 2-position thereof with one substituent selected from the group consisting of Substituent group α and Substituent group β; R3 is a group of formula (IIa); and R5 is one or two substituents which are independently selected from the group consisting of hydrogen atoms, hydroxy groups, fluorine atoms, chlorine atoms, methoxy groups, ethoxy groups, propoxy groups, methyl groups, ethyl groups, propyl groups, unsubstituted phenyl groups and phenyl groups which are substituted with substituents selected from the group consisting of Substituent group α and Substituent group β.
- 31. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R1 is a phenyl, 4-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 3,4-difluorophenyl, 3,4,5-trifluorophenyl, 3-chloro-4-fluorophenyl, 3-difluoromethoxyphenyl or 3-trifluoromethylphenyl group;
R2 is an unsubstituted 4-pyridyl or 4-pyrimidinyl group, or a 4-pyridyl or 4-pyrimidinyl group which is substituted at the 2-position thereof with one substituent selected from the group consisting of methoxy, amino, methylamino, benzylamino and α-methylbenzylamino; B is a pyrrolidine ring or a pyrroline ring; and R5 is one substituent which is independently selected from the group consisting of hydrogen atoms, methoxy groups, methyl groups, ethyl groups, propyl groups and phenyl groups.
- 32. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R1 is a phenyl, 4-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 3,4-difluorophenyl, 3,4,5-trifluorophenyl, 3-chloro-4-fluorophenyl, 3-difluoromethoxyphenyl or 3-trifluoromethylphenyl group;
R2 is an unsubstituted 4-pyridyl or 4-pyrimidinyl group, or a 4-pyridyl or 4-pyrimidinyl group which is substituted at the 2-position thereof with one substituent selected from the group consisting of methoxy, amino, methylamino, benzylamino and α-methylbenzylamino; m is 1; and R5 is one substituent which is independently selected from the group consisting of hydrogen atoms, methoxy groups, methyl groups, ethyl groups, propyl groups and phenyl groups.
- 33. The compound according to any one of claims 25 to 32, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R4 is a hydrogen atom, an unsubstituted lower alkyl group, a lower alkyl group which is substituted with one or more substituents from Substituent group α, an aryl group substituted with one or more substituents selected from the group consisting of Substituent group α. Substituent group β and Substituent group γ; an unsubstituted heterocyclyl group, or a heterocyclyl group substituted with one or more substituents selected from the group consisting of Substituent group α, Substituent group β and Substituent group γ.
- 34. The compound according to any one of claims 25 to 32, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein R4 is a hydrogen atom, a lower alkyl group, a halogeno lower alkyl group, or a phenyl group substituted with one or more substituents selected from the group consisting of Substituent group α, Substituent group β and Substituent group γ.
- 35. The compound according to any one of claims 25 to 32, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein A is a pyrazole ring having one substituent R4 or an imidazole ring having one substituent R4.
- 36. The compound according to any one of claims 25 to 32, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein A is a pyrazole ring having one substituent R4.
- 37. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein the compound is 3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-5-phenyl-4-(pyridin-4-yl)-pyrazole.
- 38. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein the compound is 5-(3-fluorophenyl)-3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.
- 39. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein the compound is 5-(4-fluorophenyl)-3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.
- 40. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein the compound is 5-(4-fluorophenyl)-3-(2-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.
- 41. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein the compound is 5-(4-fluorophenyl)-3-(2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.
- 42. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein the compound is 5-(4-fluorophenyl)-3-(2-methoxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.
- 43. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein the compound is 5-(3-chlorophenyl)-3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.
- 44. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein the compound is 5-(3,4-difluorophenyl)-3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.
- 45. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein the compound is 3-(2-ethyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-5-(4-fluorophenyl)-4-(pyridin-4-yl)pyrazole.
- 46. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, wherein the compound is 5-(4-fluorophenyl)-3-(2-propyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.
- 47. The compound according to claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof, selected from the group consisting of:
5-(4-fluorophenyl)-3-(2-hydroxy-1,2,3,5,6, 8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 3-(2-fluoro-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-5-(4-fluorophenyl)-4-(pyridin-4-yl)pyrazole, 3-(2,2-difluoro-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-5-(4-fluorophenyl)-4-(pyridin-4-yl)pyrazole, 5-(4-fluorophenyl)-3-(8-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)-5-(3-trifluoromethylphenyl)pyrazole, 5-(4-fluorophenyl)-3-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-1-methyl-4-(pyridin-4-yl)pyrazole, 3-(4-fluorophenyl)-5-(1,2,3,5,6,8a-hexahydroindolizin-7-yl)-1-methyl-4-(pyridin-4-yl)pyrazole, 3-(4-fluorophenyl)-1-methyl-5-(2-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 3-(4-fluorophenyl)-1-methyl-5-(2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 3-(4-fluorophenyl)-5-(2-hydroxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-1-methyl-4-(pyridin-4-yl)pyrazole, 3-(4-fluorophenyl)-5-(2-methoxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-1-methyl-4-(pyridin-4-yl)pyrazole, 5-(2-fluoro-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(4-fluorophenyl)-1-methyl-4-(pyridin-4-yl)pyrazole, 5-(2,2-difluoro-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-3-(4-fluorophenyl)-1-methyl-4-(pyridin-4-yl)pyrazole, 3-(4-fluorophenyl)-1-methyl-5-(8-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 5-(4-fluorophenyl)-4-(pyridin-4-yl)-3-(3,5,6,8a-tetrahydroindolizin-7-yl)pyrazole, 5-(4-fluorophenyl)-3-(1,2,3,5,8,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 5-(4-fluorophenyl)-3-(7-hydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 5-(4-fluorophenyl)-3-(1,2,3,5,6,7,8,8a-octahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 4-(4-fluorophenyl)-1-(1,2,3,5,6,7,8,8a-octahydroindolizin-7-yl)-5-(pyridin-4-yl)imidazole, 5-(4-chlorophenyl)-3-(1,2,3,5,6, 8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 5-(4-fluorophenyl)-3-(2-methyliden-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 3-(2-ethyliden-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-5-(4-fluorophenyl)-4-(pyridin-4-yl)pyrazole, 5-(4-fluorophenyl)-3-(2-propyliden-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 5-(4-fluorophenyl)-1-methyl-3-(2-methyl-1,2,3,5,6, 8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 5-(4-fluorophenyl)-1-methyl-3-(2-phenyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 5-(4-fluorophenyl)-3-(2-hydroxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-1-methyl-4-(pyridin-4-yl)pyrazole, 5-(4-fluorophenyl)-3-(2-methoxy-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-1-methyl-4-(pyridin-4-yl)pyrazole, 3-(2-fluoro-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-5-(4-fluorophenyl)-1-methyl-4-(pyridin-4-yl)pyrazole, 5-(4-fluorophenyl)-1-methyl-3-(8-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 5-(4-fluorophenyl)-3-(2-methyl-3,5,6,8a-tetrahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, 3-(2-ethyl-3,5,6,8a-tetrahydroindolizin-7-yl)-5-(4-fluorophenyl)-4-(pyridin-4-yl)pyrazole, 5-(4-fluorophenyl)-3-(2-propyl-3,5,6,8a-tetrahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole, and 5-(4-fluorophenyl)-3-(2-phenyl-3,5,6,8a-tetrahydroindolizin-7-yl)-4-(pyridin-4-yl)pyrazole.
- 48. A compound of the formula (I) below, or a pharmacologically acceptable salt, ester or other derivative thereof:
- 49. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to any one of claims 1 to 32 or 37 to 46, or a pharmacologically acceptable salt, ester or other derivative thereof, in combination with a pharmaceutically acceptable carrier.
- 50. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt, ester or other derivative thereof in combination with a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is for the prophylaxis or treatment of diseases where inflammatory cytokines are involved.
- 51. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt, ester or other derivative thereof in combination with a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is an analgesic or an anti-inflammatory drug.
- 52. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt, ester or other derivative thereof in combination with a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is for the prophylaxis or treatment of chronic rheumatoid arthritis.
- 53. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt, ester or other derivative thereof in combination with a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is for the prophylaxis or treatment of osteoarthritis.
- 54. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound according to claim 1, wherein the pharmaceutical composition is for the prophylaxis or treatment of septicemia.
- 55. A method for inhibiting the production of inflammatory cytokines in a mammal which comprises administering to said mammal a pharmaceutically effective amount of the compound of claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof.
- 56. A method for inhibiting the production of inflammatory cytokines in a human which comprises administering to said human a pharmaceutically effective amount of the compound according to any one of claims 1 to 32 or 37 to 46, or a pharmaceutically acceptable salt, ester or other derivative thereof.
- 57. A method for the relief of pain and/or the treatment of inflammation in a mammal which comprises administering to said mammal a pharmaceutically effective amount of the compound of claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof.
- 58. A method for the relief of pain and/or the treatment of inflammation in a human which comprises administering to said human a pharmaceutically effective amount of the compound according to any one of claims 1 to 32 or 37 to 46, or a pharmaceutically acceptable salt, ester or other derivative thereof.
- 59. A method for the prophylaxis or treatment of chronic rheumatoid arthritis in a mammal which comprises administering to said mammal a pharmaceutically effective amount of the compound of claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof.
- 60. A method for the prophylaxis or treatment of chronic rheumatoid arthritis in a human which comprises administering to said human a pharmaceutically effective amount of the compound according to any one of claims 1 to 32 or 37 to 46, or a pharmaceutically acceptable salt, ester or other derivative thereof.
- 61. A method for the prophylaxis or treatment of osteoarthritis in a mammal which comprises administering to said mammal a pharmaceutically effective amount of the compound of claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof.
- 62. A method for the prophylaxis or treatment of osteoarthritis in a human which comprises administering to said human a pharmaceutically effective amount of the compound according to any one of claims 1 to 32 or 37 to 46, or a pharmacologically acceptable salt, ester or other derivative thereof.
- 63. A method for the prophylaxis or treatment of septicemia in a mammal which comprises administering to said mammal a pharmaceutically effective amount of the compound of claim 1, or a pharmacologically acceptable salt, ester or other derivative thereof.
- 64. A method for the treatment of septicemia in a human which comprises administering to said human a pharmaceutically effective amount of the compound according to any one of claims 1 to 32 or 37 to 46, or a pharmacologically acceptable salt, ester or other derivative thereof.
- 65. A process for the preparation of a compound of formula (53) below
- 66. The process according to claim 65, wherein step (c) comprises
(c1) reacting a compound of formula (50) with a compound of the formula R14—NH—R15, wherein R14 and R15 are the same or different from each other and each independently represents a hydrogen atom, a lower alkyl group or an aralkyl group, or R14 and R15, taken together with the nitrogen atom to which they are attached, form a heterocyclyl group, to prepare a compound of formula (51) below 132wherein, B, R5, R24, R25, R26, R14 and R15 have the same meanings as defined above and the configuration based on the carbon atom which is marked by * represents the same configuration as the compound of formula (53); (c2) reducing an amido moiety of the compound of formula (51) to provide a compound of formula (52) below 133wherein, B, R5, R24, R25, R26, R14 and R15 have the same meanings as defined above and the configuration based on the carbon atom which is marked by * represents the same configuration as the compound of general formula (53); and (c3) subjecting the compound of formula (52) to a hydrolysis reaction to provide the compound of formula (53).
- 67. A process for the preparation of a compound of a formula (49) below which comprises subjecting a compound of formula (48) below or a reactive derivative thereof to a ring closure reaction
- 68. A process for the preparation of a compound of formula (I) below
- 69. A substantially pure optically active substance of formula (53) below
Priority Claims (2)
Number |
Date |
Country |
Kind |
2001-012881 |
Jan 2001 |
JP |
|
2001-013590 |
Jan 2001 |
JP |
|
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation-in-part application of International application PCT/JP02/00402 filed Jan. 22, 2002, the entire contents of which are hereby incorporated by reference herein.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/JP02/00402 |
Jan 2002 |
US |
Child |
10625024 |
Jul 2003 |
US |